Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMV390048 Chemoprotection in CHMI
NCT03195387Phase 1Withdrawn
- Sponsor
- Medicines for Malaria Venture
- Start
- Jan 2018
- Primary completion
- Sep 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MMV390048 in malaria (4 arms), sponsored by Medicines for Malaria Venture. Primary endpoint: Cohort-specific geometric mean time to parasitaemia up to 28 days. Planned start Jan 2018; status: withdrawn.
02
Drugs
MMV390048
03
Conditions
malaria
Beyond the preview
Go deeper on NCT03195387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03195387.